The overexpression of Polo-like kinase 1 (Plk1) promotes various cancers in humans; sporadic evidence suggests Plk1 could act as a tumor suppressor but the molecular basis for this effect are unclear. Here the authors show that Plk1 inhibition augments the tumorigenic capacity of a dominant-negative ∆APC mutant by increasing polyploidy and cell division.
- Monika Raab
- Mourad Sanhaji
- Klaus Strebhardt
